Medicine and Dentistry
Radiation Therapy
100%
Prostate Cancer
55%
Overall Survival
44%
Oropharynx Squamous Cell Carcinoma
31%
Intensity Modulated Radiation Therapy
30%
Wart Virus
26%
Neoplasm
25%
Quality of Life
20%
External Beam Radiotherapy
20%
Neck
20%
Oropharynx Carcinoma
18%
Malignant Neoplasm
17%
Hazard Ratio
16%
Brachytherapy
16%
Bladder
16%
Diseases
16%
Computer Assisted Tomography
15%
Head and Neck Squamous Cell Carcinoma
15%
Androgen Deprivation Therapy
14%
Magnetic Resonance Imaging
12%
Radiation Oncology
12%
Chemoradiotherapy
12%
P16
12%
Head and Neck Cancer
11%
Contouring
11%
Recurrent Disease
11%
High-Dose-Rate Brachytherapy
11%
Cisplatin
10%
Induction Chemotherapy
10%
Treatment Planning
9%
Pelvis
9%
microRNA
9%
Paclitaxel
9%
Image-Guided Radiation Therapy
9%
Squamous Cell Carcinoma
8%
Prostatectomy
8%
Stereotactic Body Radiation Therapy
7%
Hypofractionated Radiotherapy
7%
Metastatic Carcinoma
6%
Cetuximab
6%
Biological Marker
5%
Contralateral
5%
Transitional Cell Carcinoma
5%
Clinical Trial
5%
Drug Megadose
5%
Oncology
5%
Bladder Cancer
5%
Low Drug Dose
5%
Small-Cell Carcinoma
5%
Low and Middle Income Countries
5%
Keyphrases
Radiation Therapy
54%
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
46%
Overall Survival
45%
High-risk Human Papillomavirus (HR-HPV)
29%
Radiotherapy
25%
External Beam Radiotherapy
22%
Prostate
21%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
20%
Prostate Cancer
19%
Intensity-modulated Radiation Therapy
17%
Hazard Ratio
16%
Head-and-neck
16%
Survival Outcomes
15%
Androgen Deprivation Therapy
15%
Intermediate-risk Prostate Cancer
14%
Locally Advanced
14%
Phase II Trial
14%
Confidence Interval
14%
Quality of Life
12%
Induction Chemotherapy
12%
Tumor
11%
Head-and-neck Cancer
11%
Cisplatin
11%
P16-positive
10%
Brachytherapy
10%
HDR Brachytherapy
10%
Radiation Oncology
10%
Nab-paclitaxel
9%
Unfavorable Intermediate-risk
9%
Prostate Cancer Patients
9%
Cetuximab
8%
Treatment Plan
8%
National Cancer Database
8%
Surgically Treated
8%
Radiation Therapy for Prostate Cancer
8%
Quality Assurance
7%
Gene Signature
7%
Intraoperative Radiation Therapy
7%
Definitive Radiotherapy
7%
Bladder
7%
Chemotherapy
7%
Treatment Patterns
7%
Nasopharyngeal Carcinoma
7%
MicroRNA
6%
Disease-specific Survival
6%
Adaptive Radiotherapy
6%
Dose Escalation
6%
Odds Ratio
6%
High-grade Prostate Cancer
6%
Treatment Outcome
6%